Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

NCT06217757 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Extensive-stage Small-cell Lung Cancer

Interventions

RADIATION: Low-dose radiotherapy
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Sugemalimab
DRUG: Olaparib

Sponsor

Sichuan University